

# Classification of Human Leukemias

Gordon Chan, Jonathan Stern, Shamanth Chedde, Quinton Zerafa


# Cancer Image Archive

Blood Cell Images from **Normal** and Leukemia patients

4 Classes of Leukemia:


1. **Normal** (20,305 images)
2. **Leukemia with PML::RARA fusion** (11,584 images)
3. **Leukemia with NPM1 mutation** (17,710 images)
4. **Leukemia with CBFB::MYH11 fusion** (17,212 images)
5. **Leukemia with RUNX1::RUNX1T1 fusion** (14,403 images)

# Normal (control) vs PML::RARA Leukemia




Sample Images


## Normal (control) vs PML::RARA Leukemia




## Normal (control) vs Leukemia with RUNX1 fusion




## Normal (control) vs Leukemia with CBFB-MYH11 fusion



## Normal (control) vs Leukemia with NPM1 Mutation




# Normal (control) vs PML::RARA Leukemia




Training Loss (Post hyperparameter tuning)

Predictions	Precision	Recall	f1-Score	Support
Control	0.88	0.91	0.9	800
PML_RARA	0.91	0.88	0.9	800
Accuracy			0.9	1600
Macro Avg	0.9	0.9	0.9	1600
Weighted Avg	0.9	0.9	0.9	1600




# Normal (control) vs Leukemia with RUNX1 fusion

Predictions	Precision	Recall	f1-Score	Support
Control	0.94	0.88	0.91	800
RUNX1_RUNX1T1	0.89	0.94	0.91	800
Accuracy			0.91	1600
Macro Avg	0.91	0.91	0.91	1600
Weighted Avg	0.91	0.91	0.91	1600




# Normal (control) vs Leukemia with CBFB-MYH11 fusion

Predictions	Precision	Recall	f1-Score	Support
Control	0.79	0.93	0.86	800
CBFB-MYH11	0.92	0.75	0.83	800
Accuracy			0.84	1600
Macro Avg	0.85	0.84	0.84	1600
Weighted Avg	0.85	0.84	0.84	1600



# Normal (control) vs Leukemia with NPM1 Mutation

Predictions	Precision	Recall	f1-Score	Support
Control	0.87	0.90	0.89	800
NPM1	0.90	0.86	0.88	800
Accuracy			0.88	1600
Macro Avg	0.88	0.88	0.88	1600
Weighted Avg	0.88	0.88	0.88	1600





# Conclusion

Established 4 Image Classification models for for 4 different types of Human Leukemias.

F1 score of each model ~0.8 - 0.9.

# Conclusion


Each model was trained with ~5000 images from normal individual and from Leukemia patients.

# Dataset and Notebooks are NOW available on Kaggle

<https://www.kaggle.com/datasets/gchan357/human-aml-cytomorphology-dataset>

## Human Leukemia Cytomorphology Dataset

Dataset of Blood Cell Images from normal patients and patients with Leukemia



[Data Card](#) [Code \(5\)](#) [Discussion \(0\)](#) [Suggestions \(0\)](#)

### About Dataset

This dataset comprises blood cell images from four prevalent Acute Myeloid Leukemia (AML) subtypes with defining genetic abnormalities and typical morphological features according to the WHO 2022 classification: (i) APL with PML::RARA fusion, (ii) AML with NPM1 mutation, (iii) AML with CBFB::MYH11 fusion (without NPM1 mutation), and (iv) AML with RUNX1::RUNX1T1 fusion, as well as a control group of healthy stem cell donors.

Each folder under the root directory represent one class. These are:

- (1) normal patients (control)
- (2) APL with PML::RARA fusion (PML\_RARA)
- (3) AML with NPM1 mutation (NPM1)
- (4) AML with CBFB::MYH11 fusion without NPM1 mutation (CBFB\_MYH11)
- (5) AML with RUNX1::RUNX1T1 fusion (RUNX1\_RUNX1T1).

Each sub-folder under the folder of each class represent images from a single patient with that Leukemia. Each patient's initial is the name of that folder.

### Usability ⓘ

7.50

### License

Other (specified in description)

### Expected update frequency

Never

### Tags


Cancer

Image Classification

Diseases

**Leukemia** patients sample may contain **normal** white blood cells.

- May in part explain **misclassification**?
- Datasets needs to be **curated**?



World Health Organisation (WHO) <sup>236</sup>		Incidence	FAB type <sup>237,238</sup>	Incidence
1	AML with recurrent genetic abnormalities	30-40%		
	t(8;21)(q22;q22)		M2	25-30%
	inv(16)(p13q22) or t(16;16)(p13;q22)		M4eo	5-15%
	t(15;17)(q22;q12), (PML/RAR $\alpha$ ) and variants		M3	5-10%
	11q23 (MLL) abnormalities			
2	AML with multilineage dysplasia	10-15%		
	Following MDS or MDS/MPD			
	Without antecedent MDS or MPD, with dysplasia in at least 50% of cells in 2 or more myeloid lineages			
3	AML and MDS, therapy related	5-10%		
	Alkylating agents/radiation-related			
	Topoisomerase 2 inhibitor-related			
	Others			
4	AML, not otherwise categorised	30-40%		
	Minimally differentiated		M1	10-15%
	Without maturation		M0	2-5%
	With maturation			
	Acute myelomonocytic leukemia		M4	5-15%
	Acute monoblastic/monocytic leukemia		M5	15-25%
	Acute erythroid leukemia		M6	-3%
	Acute megakaryblastic leukemia		M7	5-10%
	Acute basophilic leukemia			
	Acute panmyelosis with myelofibrosis			
	Myeloid sarcoma			

Models presented here may be used as a **base model** to train classification of **other Leukemias** using **Transfer Learning**.

MDS indicates myelodysplastic syndrome; MPD myeloproliferative syndrome